Trial intelligence / Profile preview

Intravitreal bevacizumab as initial and adjuvant treatment in Coats' disease

2024-517036-21-00Phase 2Completed

Sponsor: Adolphe de Rothschild Foundation Hospital
Start: Nov 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, randomised trial of bevacizumab in Coats disease (2 arms), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Improvement in Shields stage at 6 months. Started Nov 2024; status: completed.

Drugs

bevacizumab

Conditions

Coats disease

Beyond the preview

Go deeper on 2024-517036-21-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-517036-21-00.